Cencora shares fall 3.3% as investors digest OneOncology integration and recent FY26 update

Cencora (COR) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: No single, widely publicized, same-day catalyst was obvious in recent filings and company updates, so the move looks more like a “digesting news” pullback than a reaction to one headline. Recent discussion around the OneOncology acquisition, capital allocation (including a pause in buybacks tied to the deal), and updated FY26 expectations may be driving incremental profit-taking after prior gains.

Details:

Cencora completed its acquisition of the OneOncology equity it did not already own in early February 2026, adding another layer of integration execution for investors to handicap.

In connection with the OneOncology transaction, the company indicated it was pausing share repurchases, which can reduce near-term support from buybacks even if fundamentals remain intact.

Following fiscal Q1 2026 results in early February, the stock saw heightened sensitivity to management commentary and outlook framing, suggesting positioning can swing on relatively small expectation changes.

At a healthcare conference appearance in March 2026, management emphasized specialty/oncolology strategy and synergies, which can also prompt investors to re-underwrite timing and margin assumptions.

Sources:

Cencora Investor Relations, Cencora (earnings materials), Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$COR Insider Trading Activity

$COR insiders have traded $COR stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $COR stock by insiders over the last 6 months:

ROBERT P. MAUCH (President & CEO) has made 0 purchases and 6 sales selling 29,244 shares for an estimated $9,920,484.
STEVEN H COLLIS (Executive Chairman) sold 31,350 shares for an estimated $9,087,142
LAZARUS KRIKORIAN (SVP & Chief Accounting Officer) sold 4,031 shares for an estimated $1,383,580
ELIZABETH S CAMPBELL (Executive Vice President) sold 3,351 shares for an estimated $1,146,377
SILVANA BATTAGLIA (Executive Vice President) sold 1,677 shares for an estimated $578,565

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$COR Hedge Fund Activity

We have seen 653 institutional investors add shares of $COR stock to their portfolio, and 707 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,321,566 shares (-73.2%) from their portfolio in Q4 2025, for an estimated $1,459,608,916
FMR LLC added 2,148,227 shares (+64.9%) to their portfolio in Q4 2025, for an estimated $725,563,669
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,085,473 shares (+80.9%) to their portfolio in Q4 2025, for an estimated $704,368,505
MARSHALL WACE, LLP removed 1,839,818 shares (-92.2%) from their portfolio in Q4 2025, for an estimated $621,398,529
VIKING GLOBAL INVESTORS LP removed 1,778,135 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $600,565,096
CITADEL ADVISORS LLC removed 1,185,912 shares (-95.8%) from their portfolio in Q4 2025, for an estimated $400,541,778
PRICE T ROWE ASSOCIATES INC /MD/ removed 731,075 shares (-9.5%) from their portfolio in Q4 2025, for an estimated $246,920,581

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$COR Government Contracts

We have seen $566,888 of award payments to $COR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PHARMACY ORDER WELIREG 40MG: $22,051

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$COR Analyst Ratings

Wall Street analysts have issued reports on $COR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Morgan Stanley issued a "Overweight" rating on 01/29/2026
TD Cowen issued a "Buy" rating on 11/10/2025
UBS issued a "Buy" rating on 11/07/2025
Mizuho issued a "Outperform" rating on 11/06/2025
Baird issued a "Outperform" rating on 11/06/2025

To track analyst ratings and price targets for $COR, check out Quiver Quantitative's $COR forecast page.

$COR Price Targets

Multiple analysts have issued price targets for $COR recently. We have seen 11 analysts offer price targets for $COR in the last 6 months, with a median target of $415.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $425.0 on 02/13/2026
Lisa Gill from JP Morgan set a target price of $419.0 on 02/10/2026
Stephen Baxter from Wells Fargo set a target price of $429.0 on 02/10/2026
John Belton from Evercore ISI Group set a target price of $420.0 on 02/05/2026
Erin Wright from Morgan Stanley set a target price of $400.0 on 01/29/2026
Brian Tanquilut from Jefferies set a target price of $440.0 on 01/22/2026
Michael Funk from B of A Securities set a target price of $360.0 on 01/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.